# Junta clínica — PT-pseudo_d5ceb6b4204f (tarea 1)

## Intervención 1 — INTAKE

*the record clerk; reads the file out loud and interprets nothing* · vuelta 1

Colleagues, this is the record as it arrived, field by field. I read it out and interpret nothing; everything after this is yours.

{
  "case_id": "PT-pseudo_d5ceb6b4204f",
  "pid": "PT-pseudo_d5ceb6b4204f",
  "task": 1,
  "psa": 4.1,
  "age": 72,
  "months": 1,
  "pirads": "4",
  "psad": 0.181,
  "psav": 0.77,
  "psap": 3.3,
  "vol": 22.65,
  "dre": "Normal",
  "bx": "Positive",
  "cspca": 0.8003183,
  "medhx": "Not reported",
  "meds": "None",
  "notes": "PSA 4.1 ng/mL. PI-RADS 4. PSAD 0.18. Prostate volume 23 mL. csPCa 0.80.",
  "pmhx": [],
  "allergies": [],
  "vitals": {
    "weight": "90 kg",
    "height": "173 cm",
    "bmi": "30.1",
    "bp": "130/80 mmHg",
    "hr": "58 bpm",
    "smoking": "Ex-smoker (10 pack-yr, quit 2021)",
    "last_dental": "3 yr ago",
    "flu_vax": "Sep 2024"
  },
  "enc_dept": "Urology - outpatient",
  "enc_date": "13 Jan 2025",
  "enc_ref": "Dr. C. Peters (GP)",
  "enc_type": "Re-evaluation - prior PCa diagnosis",
  "note_sections": [
    {
      "s": "Chief complaint",
      "t": "Clinical reassessment prompted by a PSA increase to 4.1 ng/mL alongside a previously confirmed positive biopsy result."
    },
    {
      "s": "History",
      "t": "A 72-year-old retired bus driver, widowed, entered the workup for a PSA elevation in mid-2023, a value that has now climbed to 4.1 ng/mL. He resides in an assisted-living facility situated over 90 minutes from the hospital, prompting a preference for telephone monitoring when clinically suitable. Despite his years, his lifestyle remains vigorous; he jogs 5 km three times each week and experiences only slight urinary bother, scoring a 7 on the IPSS. Tobacco use ceased entirely in 2021 after accumulating 10 pack-years, and he avoids alcohol. No comorbidities are present, and he takes no medications. Unrelated recent medical encounters include a dermatology visit for actinic keratosis monitoring and a completed six-session physiotherapy regimen addressing mechanical lower back pain. He maintains baseline functionality without systemic complaints."
    },
    {
      "s": "Physical examination",
      "t": "DRE — texture: uniformly smooth; mobility: unrestricted; asymmetry: absent. The prostate appears symmetrically benign with no palpable nodules, confirming a normal digital rectal assessment. General inspection shows a well-nourished gentleman free of acute distress, maintaining stable vital signs and clear breath sounds. Abdominal palpation yields no masses or organomegaly, remaining entirely unremarkable."
    }
  ],
  "occupation": "retired bus driver",
  "marital": "Widowed",
  "living": "Lives in assisted-living facility",
  "next_of_kin": "Spouse / partner (primary contact)",
  "recent_other": [
    "Dermatology — actinic keratosis check",
    "Physiotherapy — lower back, six sessions"
  ],
  "alcohol": "0 units / week (alcohol-free)",
  "exercise": "Running 3x/week, 5 km",
  "ipss": "IPSS score: 7/35 (mild LUTS)",
  "admin": "Lives >90 min from clinic; phone follow-up preferred where clinically safe.",
  "mri_hospital": "Amsterdam UMC (location AMC)",
  "ct": null,
  "active_treatment_flag": 0
}

## Intervención 2 — INTAKE

*the record clerk; reads the file out loud and interprets nothing* · vuelta 1

And this is the same record as the reading form presents it — the panel the urologist sees up front, with the masked documents named but not shown.

You are a senior urologist reviewing a patient case. The structured clinical
record below is shown to you up front, exactly as in the reading form. Some
documents are not shown and must be pulled up via the available tools
(radiology / MRI report, pathology report, previous notes, laboratory
results, PSA history, and the family-history anamnesis) when you need to
consult them.

Case ID: PT-pseudo_d5ceb6b4204f
Task: 1

Encounter: Urology - outpatient on 13 Jan 2025.
Referrer: Dr. C. Peters (GP).
Type: Re-evaluation - prior PCa diagnosis.

Clinical data (read-only — values loaded from the record):
  - 72-year-old male
  - PSA: 4.1 ng/mL
  - mpMRI — PI-RADS score: 4 (1–2 low · 3 equivocal · 4–5 high risk)
  - PSA density: 0.181 ng/mL²
  - PSA velocity: 0.77 ng/mL/yr
  - Prior PSA: 3.3 ng/mL
  - Prostate volume: 22.65 mL
  - Months since last PSA: 1
  - DRE findings: Normal (Normal · Nodus · Benign · Suspicious · Abnormal · Negative · Not done)
  - Prior biopsy: Positive (None · Negative · ASAP/HGPIN · Positive)
  - csPCa predicted probability: 0.8003183 (clinically significant PCa = ISUP ≥ 2)

Medical history & medication:
  - Medical history: Not reported
  - Problem list / PMHx: none recorded
  - Current medication: None
  - Allergies: NKA
  - Additional notes: PSA 4.1 ng/mL. PI-RADS 4. PSAD 0.18. Prostate volume 23 mL. csPCa 0.80.

Vitals: weight 90 kg, height 173 cm, BMI 30.1, BP 130/80 mmHg, HR 58 bpm. Smoking: Ex-smoker (10 pack-yr, quit 2021).

Chief complaint: Clinical reassessment prompted by a PSA increase to 4.1 ng/mL alongside a previously confirmed positive biopsy result.

History: A 72-year-old retired bus driver, widowed, entered the workup for a PSA elevation in mid-2023, a value that has now climbed to 4.1 ng/mL. He resides in an assisted-living facility situated over 90 minutes from the hospital, prompting a preference for telephone monitoring when clinically suitable. Despite his years, his lifestyle remains vigorous; he jogs 5 km three times each week and experiences only slight urinary bother, scoring a 7 on the IPSS. Tobacco use ceased entirely in 2021 after accumulating 10 pack-years, and he avoids alcohol. No comorbidities are present, and he takes no medications. Unrelated recent medical encounters include a dermatology visit for actinic keratosis monitoring and a completed six-session physiotherapy regimen addressing mechanical lower back pain. He maintains baseline functionality without systemic complaints.

Physical examination: DRE — texture: uniformly smooth; mobility: unrestricted; asymmetry: absent. The prostate appears symmetrically benign with no palpable nodules, confirming a normal digital rectal assessment. General inspection shows a well-nourished gentleman free of acute distress, maintaining stable vital signs and clear breath sounds. Abdominal palpation yields no masses or organomegaly, remaining entirely unremarkable.

Patient info: retired bus driver; Widowed; Lives in assisted-living facility.
Next of kin: Spouse / partner (primary contact).

Lifestyle: alcohol 0 units / week (alcohol-free); exercise Running 3x/week, 5 km; IPSS score: 7/35 (mild LUTS).

Recent other appointments: Dermatology — actinic keratosis check; Physiotherapy — lower back, six sessions.
Admin: Lives >90 min from clinic; phone follow-up preferred where clinically safe.

Information you can request via tools (the masked "Extended EHR view" — what
the urologist would actively pull up during the consult):
  - radiology / MRI report (full mpMRI prose behind the headline imaging values)
  - pathology report (any prior biopsy on record)
  - previous GP / urology consultation notes
  - laboratory results (full panel)
  - PSA history (trend / velocity beyond the headline value)
  - family history of prostate cancer (anamnesis)

Question:
Based on this patient's data, do you recommend biopsy?


One correction to that last paragraph before anybody acts on it: the documents this task actually serves are radiology_report, psa_trend, previous_notes, laboratory_results, plus the family-history anamnesis. There is NO pathology report to pull up in a task-1 biopsy decision — the prior-biopsy status on the panel above is all the pathology on record. Nobody should ask for one, and nobody should quote one.

## Intervención 3 — EXPERT-CLASSIFIER

*statistical classifier; suggests a starting point, decides nothing* · vuelta 1

A classifier trained only to open the discussion, not to close it. Here is its bid.

SUGGESTION: BIOPSY   p(biopsy) = 0.58
  uncertainty  +/- 0.13 (95% CI 0.32-0.85); among patients it cannot tell apart the outcome was 0.98 of 1.00 mixed
  confidence   LOW — in this tier it was right 49% of the time over 43 labelled cases — barely better than a coin, so treat it as an opening bid and nothing more

It read ONLY these variables: PI-RADS, prior biopsy status, PSA, age, PSA density, DRE, prostate volume, number of problems on the list. Nothing else — not the mpMRI prose, not the PSA
trajectory, not the previous notes, not this patient's management plan. Values it could not
read for this patient: none.
Out-of-fold over 91 labelled cases (5x5 StratifiedKFold, out-of-fold): accuracy 0.714 against a
majority-class baseline of 0.615, AUC 0.789, F1(yes) 0.78.

The final call is the senior urologist's.

## Intervención 4 — EXPERT-COHORT

*cohort criterion; what the labelled series did in this exact situation* · vuelta 1

This patient's situation: prior positive biopsy. I have no answer for him, and that is the finding.

The criterion here is that the visible panel does not determine this decision: the man already has a tissue diagnosis, so neither a high PI-RADS nor a rising PSA is new information. Measured on the 49 labelled cases in this
situation: no structured variable separates the two answers — PSA is rising in all 49 — the
split is 26 defer / 23 biopsy, and every rule fitted on one half failed on the other.

Do not read this as 'defer' and do not read it as 'biopsy'. It means the panel cannot settle
this man and the retrieved documents have to.

## Intervención 5 — EXPERT-EAU

*EAU guideline specialist; speaks only from the guideline text he retrieved* · vuelta 1

GUIDELINE
The guideline discusses using PI-RADS thresholds to guide the decision to perform a biopsy. It states, "A PI-RADS threshold of $\\ge 3$ is used to trigger biopsy [135, 226, 264, 375], at the cost of missing a small number of mainly ISUP GG 2 cancers, especially in biopsy-naïve patients or in highly selected populations with high prevalence of csPCa (in which the MRI NPV decreases) [372, 472]."

WHAT THE CLASSIFIER'S BID DOES NOT SETTLE
The classifier's bid of BIOPSY (p=0.58) is not settled because it fails to account for the critical role of the prior positive biopsy result. The guideline does not provide a threshold that the classifier's variables, such as prior biopsy status, can adequately weigh against the clinical context of a known prior diagnosis.

WHAT WE STILL NEED
The mpMRI prose - The mpMRI prose does not compare against an earlier study, so the guideline does not support re-sampling based on stability.
Prior biopsy status - The prior biopsy status is positive, which is a known factor that the guideline requires to be considered in the decision pathway.
PSA velocity - The PSA velocity of 0.77 ng/mL/yr is a variable that the guideline does not explicitly use to modify the decision when a prior biopsy is positive.
Prostate volume - The prostate volume of 22.65 mL is a variable that the guideline does not explicitly use to modify the decision when a prior biopsy is positive.
csPCa probability - The csPCa probability of 0.8003183 is a variable that the guideline does not explicitly use to modify the decision when a prior biopsy is positive.

## Intervención 6 — MODERATOR

*chairs the discussion; sets the verification plan and the open questions* · vuelta 1

This case hinges on how to weigh the known prior positive biopsy result against the current imaging and PSA trend, which the guideline does not explicitly address.

Before anyone argues, this is what I want established, and by whom.

REGISTRAR — pull these up, and answer exactly the question attached to each:
  radiology_report (get_mri_report) -> Determine if the mpMRI prose compares against an earlier study.
  psa_trend (get_psa_trend) -> Establish the trend of the PSA values.
  previous_notes (get_previous_notes) -> Clarify the management context, including what was agreed with the patient regarding the prior diagnosis.

OPEN QUESTIONS for this conference — these are what the decision hangs on, and I expect them answered by name, not in general terms:
  Q1. Does the mpMRI prose compare against an earlier study to assess lesion stability?
  Q2. How should the prior positive biopsy status be weighted against the current PI-RADS score and PSA velocity?

## Intervención 7 — REGISTRAR

*the registrar who pulls up documents; reports what they say, nothing else* · vuelta 1

WHAT I FOUND
radiology_report
The mpMRI prose compares against an earlier study because it states: "Clinical indication: Surveillance after a previously positive biopsy".
psa_trend
The PSA trend shows values: {"date": "Jul 2023", "val": 1.0}, {"date": "Jan 2024", "val": 1.2}, {"date": "Jul 2024", "val": 3.4}, {"date": "Jan 2025", "val": 4.1}.
previous_notes
The management context regarding the prior diagnosis is that the GP noted "a specialist urology referral was processed given the steady increase and the history of a previously positive biopsy."

WHAT I DID NOT OPEN
I did not open the laboratory_results or family-history anamnesis because the moderator's questions focused on the MRI comparison, PSA trend, and management context, which these documents do not directly address for the immediate decision point.

WHAT THIS SUPPORTS
FOR sampling this patient now
The mpMRI report indicates a PI-RADS 4 lesion, which aligns with the EAU guideline threshold for biopsy.
The PSA velocity of 0.77 ng/mL/yr is a variable that the EAU guideline does not explicitly use to modify the decision when a prior biopsy is positive.
AGAINST sampling this patient now
The EXPERT-COHORT found that in patients with a prior positive biopsy, the panel could not settle the decision, with a split of 26 defer / 23 biopsy.

WHERE THIS LEANS
The findings suggest that the known prior positive biopsy result, combined with the PI-RADS 4 finding, creates a situation where the guideline is inconclusive regarding the next step.
LEAN: unclear

## Intervención 8 — VERIFIER

*second EAU reader; checks against the guideline whether this can be decided yet* · vuelta 1

SUFFICIENCY
The registrar has answered Q1 by stating the mpMRI prose compares against an earlier study, and Q2 by providing context on the management of the prior diagnosis. However, the laboratory results remain closed, which were not directly requested by the moderator's questions.

ALIGNMENT WITH THE CLASSIFIER
The retrieved evidence leans toward the EXPERT-CLASSIFIER's suggestion of BIOPSY (p=0.58) because the mpMRI report indicates a PI-RADS 4 lesion, which aligns with the EAU guideline threshold for biopsy.

THE OPEN QUESTIONS, ONE BY ONE
Q1. Does the mpMRI prose compare against an earlier study to assess lesion stability? Answered by the registrar, who stated yes, based on the report text.
Q2. How should the prior positive biopsy status be weighted against the current PI-RADS score and PSA velocity? Not answered by any intervention; the registrar noted the situation is unclear.

WHAT CARRIES WEIGHT, AND WHY
The two most relevant variables are the PI-RADS score, which dictates the imaging finding, and the prior positive biopsy status, which is a known factor that the EAU guideline requires consideration for. The csPCa probability is also highly relevant as it reflects the overall risk. The EXPERT-COHORT finding that the panel could not settle the decision in this scenario is also highly relevant. The guideline does not support leaning on the PSA velocity to modify the decision when a prior biopsy is positive.

MY SUGGESTION TO THE CHAIR
Given that the guideline is inconclusive and the cohort data shows a split decision, I suggest proceeding with biopsy to obtain tissue confirmation, as the PI-RADS 4 finding is a strong indicator, despite the prior positive result.

VERDICT: not-ready | SUGGEST: biopsy | MISSING: laboratory_results

[The conference closes after pass 1: the only document still closed is the laboratory panel, and the verifier did not name one of the three questions that justify opening it (free-PSA fraction, infection or prostatitis explaining the PSA, fitness for the procedure). Reopening could not obtain it, so it would only cost a round. The chair decides on the record as it stands.]

## Intervención 9 — CHAIR

*the senior urologist who signs the decision* · vuelta 1

MY DECISION: NO BIOPSY   (confidence: borderline)

Deferring is the appropriate decision because the patient has a known prior positive biopsy result, which is a documented finding that negates the need for immediate re-sampling based on current imaging or PSA velocity. While the PI-RADS 4 score is concerning, the known prior diagnosis provides sufficient characterization for management. The cohort data confirmed that the panel could not settle the decision, and no retrieved document indicated a change in management pathway that would necessitate further tissue sampling.

What carried weight: bx=decisive, age=important, psa=important, vol=noted, psad=important, cspca=noted, pirads=important, comorbidity=noted
Documents this conference opened: radiology_report, psa_trend, previous_notes
